JRCT ID: jRCT1040200050
Registered date:08/10/2020
Circulating biomarkers in hormone-producing tumors
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | hormone producing endocrine tumor |
Date of first enrollment | 08/10/2020 |
Target sample size | 420 |
Countries of recruitment | |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | changes in the candidate circulating biomarker that is newly detected in this study after the treatment of its hormone-producing endocrine tumor |
---|---|
Secondary Outcome | correlation between the levels of the candidate circulating biomarker and the parameters of the physical exam or biochemistry |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | Selection criteria 1) From April 1, 2002 to December 31, 2023, a hormone-producing endocrine tumor that was diagnosed by functional tests and imaging tests at our hospital, endocrinology / metabolism internal medicine, former first internal medicine, and former second internal medicine. In addition, patients with abnormal metabolism (obesity, hypertension, abnormal glucose metabolism, cardiovascular disease, non-alcoholic fatty liver disease) who are not diagnosed as hormone production, and patients with non-hormone-producing endocrine tumors. Each diagnostic criterion follows each guideline and consensus statement. 2) Being over 20 years old and able to go to the hospital. 3) The functions of major organs (below) are retained by clinical examination within 30 days before registration. 1 White blood cell : 3,000 <= WBC <15,000 / mcL 2 Hemoglobin: Hb >= 10.0 g / dL 3 Platelet count: Platelet >= 50,000 / mcL 4 Total bilirubin: T.Bil <= 2.0 mg / dL 5 Serum creatinine: Cr <= 2.5 mg / dL 4) Patients who have received sufficient explanation before participating in this study, and who have obtained sufficient understanding and voluntary written consent of the patient. |
Exclude criteria | Exclusion criteria 1) using oral or intravenous steroids. 2) serious infection, before or after surgery, or if you have serious trauma. 3) malignant tumor (including a history). 4) the principal investigator or the investigator judges that it is inappropriate as the subject of this research. |
Related Information
Primary Sponsor | Takamura Toshinari |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Yujiro Nakano |
Address | 13-1 Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan Ishikawa Japan 920-8641 |
Telephone | +81-76-265-2711 |
yujironakano@staff.kanazawa-u.ac.jp | |
Affiliation | Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. |
Scientific contact | |
Name | Toshinari Takamura |
Address | 13-1 Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan Ishikawa Japan 920-8641 |
Telephone | +81-76-265-2711 |
ttakamura@med.kanazawa-u.ac.jp | |
Affiliation | Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. |